HRP20000436B1 - Erythropoietin derivatives - Google Patents

Erythropoietin derivatives

Info

Publication number
HRP20000436B1
HRP20000436B1 HR20000436A HRP20000436A HRP20000436B1 HR P20000436 B1 HRP20000436 B1 HR P20000436B1 HR 20000436 A HR20000436 A HR 20000436A HR P20000436 A HRP20000436 A HR P20000436A HR P20000436 B1 HRP20000436 B1 HR P20000436B1
Authority
HR
Croatia
Prior art keywords
erythropoietin
glycoprotein
group
kilodaltons
poly
Prior art date
Application number
HR20000436A
Other languages
English (en)
Croatian (hr)
Inventor
Sebastian Bailon Pascal
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20000436(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20000436A2 publication Critical patent/HRP20000436A2/hr
Publication of HRP20000436B1 publication Critical patent/HRP20000436B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HR20000436A 1999-07-02 2000-06-28 Erythropoietin derivatives HRP20000436B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14225499P 1999-07-02 1999-07-02
US15022599P 1999-08-23 1999-08-23
US15154899P 1999-08-31 1999-08-31
US16615199P 1999-11-17 1999-11-17

Publications (2)

Publication Number Publication Date
HRP20000436A2 HRP20000436A2 (en) 2001-06-30
HRP20000436B1 true HRP20000436B1 (en) 2008-01-31

Family

ID=27495518

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000436A HRP20000436B1 (en) 1999-07-02 2000-06-28 Erythropoietin derivatives

Country Status (52)

Country Link
US (2) US6583272B1 (es)
EP (2) EP1839676A3 (es)
JP (2) JP3727009B2 (es)
KR (1) KR100593143B1 (es)
CN (2) CN1184233C (es)
AR (2) AR024625A1 (es)
AT (1) ATE370748T1 (es)
AU (1) AU736067B2 (es)
BG (1) BG65449B1 (es)
BR (2) BRPI0002276B8 (es)
CA (1) CA2310536C (es)
CO (1) CO5190661A1 (es)
CY (2) CY1107719T1 (es)
CZ (1) CZ299516B6 (es)
DE (3) DE122007000064I2 (es)
DK (1) DK1064951T3 (es)
DO (1) DOP2000000030A (es)
EA (1) EA003777B1 (es)
ES (2) ES2289985T3 (es)
FR (2) FR2795734B1 (es)
GB (2) GB2393960C (es)
GC (1) GC0000197A (es)
GE (1) GEP20022804B (es)
GT (1) GT200000109A (es)
HK (2) HK1068354A1 (es)
HR (1) HRP20000436B1 (es)
HU (1) HU226233B1 (es)
ID (1) ID26447A (es)
IL (1) IL137056A0 (es)
IS (1) IS2492B (es)
IT (1) IT1318606B1 (es)
LU (1) LU91363I2 (es)
MA (1) MA26746A1 (es)
MX (1) MXPA00006547A (es)
MY (1) MY128500A (es)
NL (1) NL300289I9 (es)
NO (2) NO327043B1 (es)
NZ (1) NZ505454A (es)
OA (1) OA11442A (es)
PA (1) PA8497801A1 (es)
PE (1) PE20010297A1 (es)
PL (1) PL202758B1 (es)
PT (1) PT1064951E (es)
RS (1) RS49928B (es)
SG (1) SG92717A1 (es)
SI (1) SI1064951T1 (es)
SK (1) SK286301B6 (es)
SV (1) SV2002000120A (es)
TN (1) TNSN00147A1 (es)
TR (1) TR200001956A2 (es)
TW (1) TWI235667B (es)
UY (1) UY26228A1 (es)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
JP2002511432A (ja) * 1998-04-15 2002-04-16 レキシジェン ファーマシューティカルズ コーポレイション 新脈管形成インヒビターの同時投与による抗体−サイトカイン融合タンパク質媒介性免疫応答の増強
US7304150B1 (en) * 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
KR100827757B1 (ko) * 1999-08-09 2008-05-07 메르크 파텐트 게엠베하 복수의 시토킨-항체 복합체
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
ATE336514T1 (de) * 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DK1311285T4 (en) † 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
JP5170931B2 (ja) * 2000-10-16 2013-03-27 中外製薬株式会社 Ｐｅｇ修飾エリスロポエチン
WO2002049673A2 (en) * 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
AU3323002A (en) * 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
EP1366067B1 (en) * 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
AU2002308562B2 (en) * 2001-05-03 2008-01-24 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
KR100467751B1 (ko) 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
ES2414706T3 (es) * 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
US7129267B2 (en) 2002-03-11 2006-10-31 Janssen Pharmaceutica N.V. Methods for SHP1 mediated neuroprotection
EP1552298A4 (en) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc RECOMBINANT TISSUE-PROOFING CYTOKINS AND NUCLEIC ACIDS COORDINATING THEREOF FOR THE PROTECTION, RECOVERY AND IMPROVEMENT OF CELLS, TISSUE AND ORGANS THEREOF
PL375265A1 (en) 2002-07-24 2005-11-28 F.Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
BR0314107A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Método de produção de derivados de hidroxialquil amido
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
PL211180B1 (pl) * 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7587286B2 (en) 2003-03-31 2009-09-08 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
CA2525568C (en) * 2003-05-12 2017-07-25 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP2204193A3 (en) * 2003-05-12 2010-08-18 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
EA010099B1 (ru) * 2003-05-12 2008-06-30 Афимакс, Инк. Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения
CN1820024B (zh) * 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
JP2007537986A (ja) * 2003-05-30 2007-12-27 セントカー・インコーポレーテツド トランスグルタミナーゼを用いる新規なエリトロポエチン複合体の形成
WO2005011587A2 (en) * 2003-07-30 2005-02-10 New Century Pharmaceuticls Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1670492A4 (en) * 2003-09-29 2009-07-08 Warren Pharmaceuticals Inc FABRIC PROTECTION CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPTICEMIA AND THE FORMATION OF ADHESIONS
WO2005035564A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
PL1696947T3 (pl) * 2003-12-19 2014-08-29 Hoffmann La Roche Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit
EP1548031A1 (en) * 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
AU2005206549B2 (en) * 2004-01-21 2011-09-15 Nektar Therapeutics Method of preparing propionic acid-terminated polymers
ZA200606225B (en) * 2004-02-02 2007-11-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
AR048035A1 (es) 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US7253650B2 (en) 2004-05-25 2007-08-07 International Business Machines Corporation Increase productivity at wafer test using probe retest data analysis
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
AU2005310189A1 (en) * 2004-11-11 2006-06-08 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006081249A2 (en) 2005-01-25 2006-08-03 Cell Therapeutics, Inc. Conjugates of biologically active proteins having a modified in vivo half-life
EP1848461A2 (en) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
ES2357152T3 (es) * 2005-10-04 2011-04-19 Zymogenetics, L.L.C. Producción y purificación de il-29.
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
CN101291684A (zh) * 2005-10-21 2008-10-22 阿维季尼克斯股份有限公司 甘醇化和糖基化的禽类来源的治疗性蛋白
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
US20130172274A1 (en) * 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20100166700A1 (en) 2006-02-28 2010-07-01 Oligasis Corporation Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation
JP5553506B2 (ja) 2006-03-22 2014-07-16 中外製薬株式会社 エリスロポエチン溶液製剤
WO2008019214A1 (en) * 2006-08-04 2008-02-14 Prolong Pharmaceuticals, Inc. Modified erythropoietin
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
EP2120998B1 (en) 2006-11-28 2013-08-07 HanAll Biopharma Co., Ltd. Modified erythropoietin polypeptides and uses thereof for treatment
WO2008097461A2 (en) * 2007-02-02 2008-08-14 Amgen Inc Hepcidin and hepcidin antibodies
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
CA2701032C (en) 2007-09-27 2021-01-26 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
EP2235090B1 (en) 2008-01-11 2013-09-04 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20100003238A1 (en) 2008-04-14 2010-01-07 Frost Gregory I Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
CN104922669A (zh) 2008-11-13 2015-09-23 通用医疗公司 用于通过调整bmp-6来调节铁稳态的方法和组合物
EP3037529B1 (en) 2008-12-09 2019-03-27 Halozyme, Inc. Extended soluble ph20 polypeptides and uses thereof
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
JP5813638B2 (ja) 2009-07-30 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 可動クロマトグラフィーカラムセパレータ
WO2011024025A1 (en) * 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
CA2775012A1 (en) * 2009-09-23 2011-03-31 Biogenerix Ag Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
AU2010310457B2 (en) 2009-10-23 2015-07-02 Amgen Inc. Vial adapter and system
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
JP2013525406A (ja) * 2010-04-27 2013-06-20 スキル テクノロジー ゲーエムベーハー 安定ｍｉａ／ｃｄ−ｒａｐ製剤
RS54291B2 (sr) 2010-06-07 2023-12-29 Amgen Inc Uređaj za isporuku lekova
KR20130125753A (ko) 2010-07-20 2013-11-19 할로자임, 아이엔씨 항-히알루로난제 투여와 관련된 유해 부작용의 치료
CA2808748C (en) 2010-09-14 2018-09-11 Roberto Falkenstein Method for purifying pegylated erythropoietin
WO2012104278A1 (en) 2011-02-02 2012-08-09 F. Hoffmann-La Roche Ag Chromatography column support
EP2907504B1 (en) 2011-02-08 2017-06-28 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
CA3145238A1 (en) 2011-04-20 2012-10-26 Amgen Inc. Autoinjector apparatus
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
CA2851521C (en) 2011-10-14 2020-09-22 Amgen Inc. Injector and method of assembly
EP2771028A2 (en) 2011-10-24 2014-09-03 Halozyme, Inc. Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
EP4338797A3 (en) 2011-12-02 2024-06-12 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
JP6067746B2 (ja) 2011-12-30 2017-01-25 ハロザイム インコーポレイテッド Ｐｈ２０ポリペプチド変異体、その製剤および使用
JP6042527B2 (ja) 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
AU2013348071B2 (en) 2012-11-21 2018-05-24 Amgen Inc. Drug delivery device
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
WO2014143815A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
LT2976117T (lt) 2013-03-22 2021-02-25 Amgen Inc. Purkštuvas ir surinkimo būdas
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
SI3041513T1 (sl) 2013-09-08 2020-11-30 Kodiak Sciences Inc. Zwitterionski polimerni konjugati faktorja VIII
EP3501575B1 (en) 2013-10-24 2021-12-01 Amgen Inc. Drug delivery system with temperature-sensitive-control
BR112016008946B1 (pt) 2013-10-24 2022-12-27 Amgen Inc Injetores e método para montar os injetor
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
EP3139977B1 (en) 2014-05-07 2021-02-17 Amgen Inc. Autoinjector with shock reducing elements
SG11201609966SA (en) 2014-06-03 2016-12-29 Amgen Inc Drug delivery system and method of use
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
ES2727137T3 (es) 2014-08-28 2019-10-14 Halozyme Inc Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
MX2021014323A (es) 2014-10-14 2023-02-02 Amgen Inc Dispositivo de inyección de fármaco con indicadores visuales y audibles.
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
EP3556411B1 (en) 2015-02-17 2021-06-30 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
PL3484911T3 (pl) 2016-07-15 2021-03-08 F. Hoffmann-La Roche Ag Sposób oczyszczania PEGylowanej erytropoetyny
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
CA3048520A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP2020508803A (ja) 2017-03-06 2020-03-26 アムジエン・インコーポレーテツド 作動防止特徴部を備える薬物送達デバイス
SG11201908058UA (en) 2017-03-07 2019-09-27 Amgen Inc Needle insertion by overpressure
KR102619150B1 (ko) 2017-03-09 2023-12-27 암겐 인코포레이티드 약물 전달 장치용 삽입 메커니즘
JP2020511499A (ja) 2017-03-20 2020-04-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
SI3600491T1 (sl) 2017-03-28 2023-11-30 Amgen Inc. Sistem in postopek za sestavljanja droga bata in brizge
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CN110709121B (zh) 2017-06-08 2022-06-24 安进公司 扭矩驱动式药物递送装置
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
MX2019015402A (es) 2017-06-22 2020-07-20 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso.
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. ELECTRONIC DRUG DELIVERY DEVICE COMPRISING A CAP ACTIVATED BY A SWITCH ASSEMBLY
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
MA50527A (fr) 2017-11-03 2020-09-09 Amgen Inc Système et approches pour stériliser un dispositif d'administration de médicament
EP3706830B1 (en) 2017-11-06 2024-08-07 Amgen Inc. Drug delivery device with placement and flow sensing
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
EP3731871B1 (en) 2017-12-29 2023-10-04 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
EP3731872B1 (en) 2017-12-29 2021-11-24 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
EP3731873B1 (en) 2017-12-29 2022-01-26 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
MA53375A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
US12109389B2 (en) 2018-07-31 2024-10-08 Amgen Inc. Fluid path assembly for a drug delivery device
EP3613486B1 (de) * 2018-08-24 2020-10-07 UGA Biopharma GmbH Verfahren und anlage zur reinigung von epo und/oder einem epo-derivat
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
AU2019350660B2 (en) 2018-09-28 2024-09-26 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CN117159846A (zh) 2018-10-02 2023-12-05 安进公司 具有内部力传递的用于药物递送的注射系统
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
MX2021002791A (es) 2018-10-15 2021-05-12 Amgen Inc Proceso de ensamblaje de plataforma para un dispositivo de administracion de farmacos.
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CA3137360A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022063082A1 (zh) 2020-09-22 2022-03-31 美国杰科实验室有限公司 一种糖基化修饰的促红细胞生成素及其应用
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
IL308169A (en) 2021-05-10 2024-01-01 Chiome Bioscience Inc Purification method of an antibody compound
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions
CN116492448A (zh) * 2023-04-12 2023-07-28 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
IL110669A (en) * 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE741187T1 (de) 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ES2208798T3 (es) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
CA2352538A1 (en) 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
WO2001068141A2 (en) 2000-03-17 2001-09-20 Maxygen Aps Dispersions of polypeptide conjugates
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DK1311285T4 (en) * 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative

Also Published As

Publication number Publication date
ATE370748T1 (de) 2007-09-15
AU4274400A (en) 2001-01-04
JP2001064300A (ja) 2001-03-13
PT1064951E (pt) 2007-09-10
FR07C0051I2 (fr) 2008-05-09
AU736067B2 (en) 2001-07-26
NL300289I1 (nl) 2007-11-01
CY1107719T1 (el) 2010-07-28
EA200000607A1 (ru) 2001-02-26
GT200000109A (es) 2001-12-21
FR07C0051I1 (es) 2007-12-14
GB2393960C (en) 2012-08-29
ES2191511A1 (es) 2003-09-01
NL300289I9 (nl) 2019-08-21
DE10031839A1 (de) 2001-02-01
MY128500A (en) 2007-02-28
CN1515590A (zh) 2004-07-28
LU91363I2 (fr) 2007-11-12
DK1064951T3 (da) 2007-10-08
NO2009010I1 (no) 2009-05-25
GEP20022804B (en) 2002-09-25
GB0016205D0 (en) 2000-08-23
CY2007021I1 (el) 2009-11-04
MA26746A1 (fr) 2004-12-20
NO20003372L (no) 2001-01-03
GB2393960A (en) 2004-04-14
TWI235667B (en) 2005-07-11
CA2310536A1 (en) 2001-01-02
CN1280137A (zh) 2001-01-17
KR100593143B1 (ko) 2006-06-26
IL137056A0 (en) 2001-06-14
SG92717A1 (en) 2002-11-19
NO2009010I2 (no) 2014-06-02
CO5190661A1 (es) 2002-08-29
HRP20000436A2 (en) 2001-06-30
EP1839676A2 (en) 2007-10-03
HUP0002553A3 (en) 2005-11-28
DE60036053D1 (de) 2007-10-04
NO20003372D0 (no) 2000-06-28
FR2795734B1 (fr) 2005-09-30
NZ505454A (en) 2001-12-21
AR024625A1 (es) 2002-10-16
TNSN00147A1 (fr) 2005-11-10
BRPI0002276B1 (pt) 2019-05-14
EP1839676A3 (en) 2008-09-03
KR20010049676A (ko) 2001-06-15
BRPI0002276B8 (pt) 2021-05-25
IS2492B (is) 2009-02-15
CZ299516B6 (cs) 2008-08-20
BG104570A (en) 2001-09-28
BG65449B1 (bg) 2008-08-29
GB0400086D0 (en) 2004-02-04
BR0002276A (pt) 2001-12-11
CA2310536C (en) 2007-09-11
US6583272B1 (en) 2003-06-24
EP1064951A3 (en) 2002-03-20
EP1064951A2 (en) 2001-01-03
JP2004155787A (ja) 2004-06-03
UY26228A1 (es) 2000-10-31
ITMI20001479A0 (it) 2000-06-30
HK1033328A1 (en) 2001-08-24
SK9872000A3 (en) 2002-06-04
CZ20002386A3 (cs) 2002-04-17
NL300289I2 (nl) 2010-02-01
CY2007021I2 (el) 2009-11-04
HU0002553D0 (en) 2000-08-28
GB2393960B (en) 2004-08-04
RS49928B (sr) 2008-09-29
SV2002000120A (es) 2002-01-31
PL341187A1 (en) 2001-01-15
DE60036053T2 (de) 2008-01-03
YU40700A (sh) 2003-12-31
GB2353281A (en) 2001-02-21
ITMI20001479A1 (it) 2001-12-30
CN1184233C (zh) 2005-01-12
TR200001956A2 (tr) 2001-01-22
IT1318606B1 (it) 2003-08-27
AR055650A2 (es) 2007-08-29
ID26447A (id) 2001-01-04
GC0000197A (en) 2006-03-29
LU91363I9 (es) 2018-12-31
HU226233B1 (en) 2008-07-28
HUP0002553A2 (en) 2001-03-28
IS5554A (is) 2001-01-02
NO327043B1 (no) 2009-04-06
DE122007000064I2 (de) 2010-03-25
US20030120045A1 (en) 2003-06-26
DE122007000064I1 (de) 2008-01-03
JP3727009B2 (ja) 2005-12-14
SK286301B6 (en) 2008-07-07
GB2353281B (en) 2004-06-09
EP1064951B1 (en) 2007-08-22
MXPA00006547A (es) 2004-10-28
PA8497801A1 (es) 2001-12-14
OA11442A (fr) 2004-04-28
DOP2000000030A (es) 2002-07-15
EA003777B1 (ru) 2003-08-28
HK1068354A1 (en) 2005-04-29
PE20010297A1 (es) 2001-03-07
ES2191511B1 (es) 2005-01-01
PL202758B1 (pl) 2009-07-31
CN1283664C (zh) 2006-11-08
FR2795734A1 (fr) 2001-01-05
ES2289985T3 (es) 2008-02-16
SI1064951T1 (sl) 2007-12-31

Similar Documents

Publication Publication Date Title
HRP20000436B1 (en) Erythropoietin derivatives
HRP20010966B1 (en) Erythropoietin conjugates with polyethylenglycol
DE60144439D1 (de) Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
ES2376888T3 (es) Materiales supramoleculares activos biológicamente, modulares biorreabsorbibles o biomédicos
EP0340741A3 (en) Polyethylene glycol derivatives, modified peptides and production thereof
RS49533B (sr) Interferonski konjugati
ATE298775T1 (de) Antistatische polymerzusammensetzungen
DE69114614D1 (de) Polyethylenglykolderivate, modifizierte Peptide derselben, ihre Herstellung sowie Verwendung der modifizierten Peptide.
AR035407A1 (es) Conjugados de eritropoyetina, composiciones farmaceuticas que los comprenden, uso de dichos conjugados en la preparacion de medicamentos, proceso para preparar dichos conjugados y glicoproteinas de eritropoyetina
AR041061A1 (es) Uso de la eritropoyetina en pacientes con diabetes
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
AR016561A1 (es) Polipeptido modificado; composiciones para la higiene, para la limpieza, para el cuidado de la piel y humectante de la piel; y gel para la ducha
SE0101523D0 (sv) Linjär polymer
JO2257B1 (en) Erythropoietin derivatives
TH52291B (th) อนุพันธ์อีริโทรโพอีทิน
CN114025846A (zh) 用于治疗关节疾病的药物组合物及其制备方法
ECSP003557A (es) Derivados de eritropoyetina
ECSP003558A (es) Derivados de eritropoyetina
UY26229A1 (es) Derivados de la eritopoyetina
TH62376A (th) Peg คอนจูเกตของ hgf-nk4

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190604

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200628